Dr. Dong Liu, Ph.D., serves as our chief execute office (CEO) since 2015. Prior to founding Kind Pharmaceuticals, Dong was a project leader of Fibrogen and a senior pharmacologist at Merck. With over 10 years’ experience in both Pharma giant and innovative biotech, Dong has evolved to a seasoned scientist with expertise on pharmacology, PK, and toxicology. Dong was a research assistant professor at University of Rochester before entering industry. Dong holds a Ph.D. degree in pharmacology from China Marine University, and bachelor and master’s degree in Pharmacy in Shandong University in China. Dong received his postdoctoral training at Max-Planck-Institute of Psychiatry in Germany. Dong published multiple peer reviewed articles in Nature Medicine, Nature Neuroscience, Neuron, Circulation, etc.
Dr. Qi Zhu, M.D., joined Kind as the Chief Medical Officer (CMO) and the member of board of directors in early 2019 with near 30 years’ extensive experience in global clinical drug development in the pharmaceutical industries. Before joining Kind, he was a senor medical officer at Baxalta/Shire, where he successfully led ONIVYDE® global clinical development and approvals. Prior to that, he was the Global Head of Clinical R&D in BMS MI and Lantheus (a BMS span-off) for over twelve years, where he was responsible for 6 pipelines’ development and 3 products’ life cyclic management. He managed about 80 protocols from phase I to phase IV; 4 NDA/sNDA/MAA and 3 IND submissions; and achieved 3 new approvals. Prior to joining BMS, Dr. Zhu was the Executive Clinical Director at ABR, a full service CRO, where he led execution of the clinical and regulatory affairs programs. Dr. Qi Zhu earned a M.D. degree from Suzhou University Medical School, China, and he completed his clinical post-doctoral training and clinical research fellowship at Schepens Eye Research Institute, MEEI and Harvard Medical School where he stayed on staff, as PI or co-PI, to focus on clinical research for new drug development, prior to transitioning to healthcare industry.
Dr. Qiang Xu, Ph.D., is a Partner at Decheng Capital, and he has been with the firm since inception. He is currently serving on the boards of Kind Pharmaceutical, BCFoods, GYT HealthCare Services, IMPACT Therapeutics, KeChow Pharma, and Shenyi Bio. He has over 14 years’ experience from biotechnology start-ups to pharmaceutical companies. He also has extensive experience in agricultural biotechnology. He was most recently the Vice President of Research at Osel and the principal investigator for multiple grants funded by the NIH and other foundations. Dr. Xu started his biotechnology career at Bayer, then worked at Pan Pacific Pharmaceuticals as a director, and Scios as a member of the Alzheimers Disease Discovery Program. He has published over 30 peer reviewed papers, and 50 conference presentations, and he is the co-inventor of 10 patents or applications. Dr. Xu received his PhD degree in Plant Physiology from Kansas State University. He completed his postdoctoral training at the University of California, Berkeley.
Pandy Song, joined NLVC in 2016 and brought with him a profound understanding of China’s pharmaceutical industry. He has extensive experience in corporate strategic planning and implementation, along with a background in clinical trial applications, business development, team building, and marketing management. His primary areas of focus at NLVC are biotech and biopharmaceuticals, with notable investments including SHIP, Connect Biopharma, Belief Biomed, and NGGT.
Prior to NLVC, Pandy worked in the Department of Strategic Research at Staidson Biopharmaceutical Co., Ltd., where he handled business development work surrounding global licensing and strategic alliance management, including joint ventures, partnerships, and value-add collaborations. Additionally, he led marketplace assessments of China’s pharmaceutical industry, including policy work and trend identification, before ultimately helping develop the company’s longterm strategy and dynamic modeling processes. Before joining the Strategic Research team, Pandy served as manager of Staidson’s Department of Pharmacology, where he assisted in the design and development of clinical trials, and where he was responsible for new drug registration processes and clinical assessments.
Pandy holds a PhD in Biophysics from the Chinese Academy of Medical Sciences, a PhD in Philosophy from Peking Union Medical College, and a master’s degree in Biochemical Engineering from the Beijing Institute of Technology.
Dr. Shaojiang Deng, Ph.D., is the Chief Scientific Officer (CSO) at Kind. He has rich and successful experience in organic synthesis (25+ years) and drug discovery, development, and manufacturing (15+ years), and has broad bench-to-bedside knowledge in drug industry. He held titles in research position from scientist to principal scientist at FibroGen (2004-2019) and was awarded several times for critical contributions at FibroGen. He conducted postdoctoral research at Harvard Medical School and UCSF (1999-2004). He obtained Ph.D. from Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences (1999); he is the recipient of multiple national and regional awards in China.
